Savara Q1 net loss widens on higher R&D costs

Savara

12/05/2026 21:16

Overview

US rare respiratory drug developer's Q1 net loss widened yr/yr on higher R&D and admin costs

Company increased spending on MOLBREEVI program and share-based compensation

Savara ended Q1 with $203 mln in cash, says well capitalized for potential MOLBREEVI launch

Outlook

Savara expects FDA decision on MOLBREEVI by Nov 22, 2026

Company anticipates EMA decision in Q1 2027 and UK MHRA decision in Q4 2026

Savara says it is preparing for potential commercial launch of MOLBREEVI

Result Drivers

MOLBREEVI PROGRAM COSTS - Higher R&D expenses were mainly due to increased activities for the MOLBREEVI program, including manufacturing and personnel costs

SHARE-BASED COMPENSATION - Increased share-based compensation drove up both R&D and administrative expenses

Company press release: ID:nBw98PXZ4a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.15
Q1 Net Income
-$37.28 mln
Q1 Income from Operations
-$38.99 mln
Q1 Operating Expenses
$38.99 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Savara Inc is $10.25, about 100.2% above its May 11 closing price of $5.12

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)